Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association endorsed by the American Society for Radiation Oncology

Levine, Glenn N., D'Amico, Anthony V., Berger, Peter, Clark, Peter E., Eckel, Robert H., Keating, Nancy L., Milani, Richard V., Sagalowsky, Arthur I., Smith, Matthew R. and Zakai, Neil (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association endorsed by the American Society for Radiation Oncology. Circulation, 121 6: 833-840. doi:10.1161/CIRCULATIONAHA.109.192695


Author Levine, Glenn N.
D'Amico, Anthony V.
Berger, Peter
Clark, Peter E.
Eckel, Robert H.
Keating, Nancy L.
Milani, Richard V.
Sagalowsky, Arthur I.
Smith, Matthew R.
Zakai, Neil
Title Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association endorsed by the American Society for Radiation Oncology
Journal name Circulation   Check publisher's open access policy
ISSN 0009-7322
1524-4539
Publication date 2010-02-01
Year available 2010
Sub-type Article (original research)
DOI 10.1161/CIRCULATIONAHA.109.192695
Open Access Status Not Open Access
Volume 121
Issue 6
Start page 833
End page 840
Total pages 8
Place of publication Baltimore, MD, United States
Publisher Lippincott Williams & Wilkins
Language eng
Formatted abstract
Androgen-deprivation therapy (ADT) is a widely used treatment for prostate cancer. Recently, several studies have reported an association between ADT and an increased risk of cardiovascular events, including myocardial infarction and cardiovascular mortality.1–5 These reports have led to increased interest and discussion regarding the metabolic effects of ADT and its possible association with increased cardiovascular risk. In addition, likely as a result of these reports, internists, endocrinologists, and cardiologists are now being consulted regarding the evaluation and management of patients in whom ADT is being initiated. Most of these physicians are not aware of the possible effects of ADT on cardiovascular risk factors or the issues regarding ADT and cardiovascular disease. Therefore, this multidisciplinary writing group has been commissioned to review and summarize the metabolic effects of ADT, to evaluate the data regarding a possible relationship between ADT and cardiovascular events in patients with prostate cancer, and to generate suggestions regarding the evaluation and management of patients, both with and without known cardiac disease, in whom ADT is being initiated.

The writing group emphasizes that the purpose of this advisory is strictly informative. This advisory should thus not be construed as dictating clinical practice or superseding the clinical judgment of physicians, and it should not be used for medicolegal purposes.
Keyword AHA Scientific Statements
Cardiovascular risk
Prostate cancer
Androgen-deprivation therapy
Q-Index Code C1
Q-Index Status Confirmed Code
Grant ID K24 CA121990
Institutional Status Non-UQ
Additional Notes on behalf of the American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
ERA 2012 Admin Only
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 151 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 167 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 14 Mar 2011, 19:49:59 EST